Although ACC1/ACC2 dual inhibitors have been effective for the management of MASLD in the preclinical setting, the associated hypertriglyceridemia often observed in ACCi-based therapies represents a critical limitation for its clinical implementation. Here, ACACB is linked to hypertriglyceridemia.